Rationale and application of beta-2-microglobulin measurements to detect acute transplant rejection

Nephron
D M RoxeJ Wolf

Abstract

Serum and urinary concentrations of beta 2-microglobulin were measured for the first 21 days after renal transplantation to aid in diagnosis of acute rejection. Criteria developed after study of 15 patients were applied to the entire group of 31 consecutive cases. 29 instances meeting our criteria were identified in 651 days at risk and were associated with a mean maximal increase of serum creatinine of 74.8%. beta 2-Microglobulin methods may make possible detection of what is now subclinical rejection. beta 2-Microglobulin methods, however, are an adjunct to, not a replacement for classical methods for detecting acute rejection.

Citations

Sep 6, 2007·World Journal of Urology·Wilfried Gwinner
Jul 1, 2006·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Mona KhuranaAsher D Schachter
Sep 18, 1997·Transplantation Proceedings·E ErezB A Vidne
May 27, 2010·Molecular & Cellular Proteomics : MCP·Gabriela V Cohen FreueUNKNOWN Genome Canada Biomarkers in Transplantation Group
Apr 18, 2013·PLoS Computational Biology·Gabriela V Cohen FreueUNKNOWN Biomarkers in Transplantation and the NCE CECR Prevention of Organ Failure Centre of Excellence Teams
Nov 3, 2006·Expert Review of Proteomics·Stefan SchaubPeter Nickerson
Mar 28, 2001·The American Journal of the Medical Sciences·M HayashiN Inaba
Nov 1, 1987·Kidney International·G H Schardijn, L W Statius van Eps
Feb 13, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Masatoshi HayashiNoriyuki Inaba
Jan 1, 1986·Journal of Hepatology·J A Solis-HerruzoA Schüller
Jan 1, 1983·Clinical and Experimental Dialysis and Apheresis·K V Rao, C M Kjellstrand
Mar 12, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Stefan SchaubPeter Nickerson
Dec 1, 1989·DICP : the Annals of Pharmacotherapy·G L KearnsJ T Wilson
Aug 29, 1981·Lancet·M L FoeghG E Schreiner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.